5 Minutes Read
Launch of Trastuzumab in US market offers a sizeable opportunity for Biocon & Mylan, says Kiran Mazumdar Shaw
KV Prasad Jun 13, 2022, 06:35 AM IST (Published)
Listen to the Article (6 Minutes)
Summary
Biocon and Mylan have launched a cancer drug Trastuzumab in the United States. The size of the drug is USD 2.5 to 2.8 billion in the US market.
Biocon and Mylan have launched a cancer drug Trastuzumab in the United States. The size of the drug is USD 2.5 to 2.8 billion in the US market and Biocon is estimated to make USD 70 to 100 million in peak sales.
Speaking at length about this development Kiran Mazumdar Shaw, CMD of the company said they entered the US market after being the first to be approved but Amgen (pharma company) launched Trastuzumab at risk. Apart from Amgen there are two other approvals as well, she added.
“However, we believe that the space is still not crowded. We believe that this is a very important segment for us. The market dynamics are about ensuring access to this very important breast cancer drug and we believe that Mylan and Biocon are committed to this end and we believe that we are able to offer affordable access to this lifesaving breast cancer drug,” she added.
“We believe we will have a pretty major impact on this market opportunity and can get a sizeable share of the market despite 4 other competitors that we will have to contend with,” she further said in an interview with CNBC-TV18.
“We have a profit share arrangement with Mylan and we believe that the opportunity is sizeable for both Myland and Biocon,” she said, adding that they would be able to share more accurate estimates as they enter the market and see how they fair.
Not committing to any number, she said there are estimates that analysts have assessed from the market size and market dynamics.
She said they got both the dosage forms of 440 and 150 mg, which puts them in a strong position to garner market share. “The 150 mg formulation is the dominant formulation, which Biocon has in terms of approval,” she added.
On biosimilars front, the CMD said, “This is our second biologics to be marketed or commercialized in the US. The first being Pegfilgrastim. So we do have a growing portfolio of biosimilar antibodies for cancer. The next being Bevacizumab. So as a company Mylan and Biocon are well positioned to be strong player in this whole oncology space.”
We have a significant presence in some of the among emerging markets for Trastuzumab , said Mazumdar Shaw.
Talking about their sales target of USD 1 billion for biosimilars by FY22 she said, “At the moment we are very much on track. We believe that we can get even more confident once our products enter the markets and we see the kind of market share we are garnering, but at this point in time we remain confident of hitting that target.”
Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout
3 Mins Read
Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter
Daily Newsletter
